Matsuno Hiroyuki, Kozawa Osamu, Okada Kiyotaka, Ueshima Shigeru, Matsuo Osamu, Uematsu Toshihiko
Department of Pharmacology, Gifu University School of Medicine, Japan.
Thromb Haemost. 2002 Jan;87(1):98-104.
The role of plasminogen (Plg) and alpha2-antiplasmin (alpha2-AP) in vascular thrombolysis in vivo was investigated in mice deficient in plasminogen (Plg-/-) or a2-AP (alpha2-AP-/-) or their wild type (PAI-1+/+, alpha2-AP+/+). A thrombus was induced in the murine carotid artery or the internal jugular vein by endothelial injury. Blood flow was continuously monitored for 90 min and for 6 h 30 min after the initiation of endothelial injury. The times to occlusion by the developing thrombus in the carotid artery and the jugular vein of wild type mice were 12+/-1.8 and 7.2+/-1.9 min, respectively. The arterial thrombus formation in alpha2-AP-/- mice was indistinguishable from the one in wild type mice, whereas the time to occlusion in Plg-/- was significantly shortened to 5.9+/-1.7 min. Vascular patency after spontaneous reperfusion was markedly improved in alpha2-AP-/- mice. On the contrary, arteriarpatency in Plg-/- mice was aggravated. In venous thrombus formation, the time to occlusion in alpha2-AP-/- mice was significantly prolonged (27.1+/-5.2 min), whereas in Plg-/- it was slightly shortened to 6.5+/-2.5 min. Vascular patency after spontaneous reperfusion was also improved in alpha2-AP-/- mice, but not in Plg-/- mice. Histological observations using SEM indicated that fibrin nets were firmly fixed on the injured area in Plg-/- mice, but not in alpha2-AP-/- mice. The tail bleeding time was not different in any type of mice. However, re-bleeding time using a template bleeding device was significantly prolonged in alpha2-AP-/- as compared with that of wild type mice. In conclusion, lack of plasminogen markedly reduces the antithrombotic activities in vivo, whereas alpha2-AP plays a more important role in the formation and removal of venous thrombus in mice. Consequently, the inhibition of alpha2-AP could be a useful tool for the therapy of venous thrombosis and the prevention of re-thrombus formation.
在缺乏纤溶酶原(Plg-/-)或α2-抗纤溶酶(α2-AP-/-)或其野生型(PAI-1+/+,α2-AP+/+)的小鼠中,研究了纤溶酶原(Plg)和α2-抗纤溶酶(α2-AP)在体内血管溶栓中的作用。通过内皮损伤在小鼠颈动脉或颈内静脉诱导血栓形成。在内皮损伤开始后,连续监测血流90分钟和6小时30分钟。野生型小鼠颈动脉和颈静脉中血栓形成导致血管闭塞的时间分别为12±1.8分钟和7.2±1.9分钟。α2-AP-/-小鼠的动脉血栓形成与野生型小鼠无异,而Plg-/-小鼠血管闭塞时间显著缩短至5.9±1.7分钟。α2-AP-/-小鼠自发再灌注后的血管通畅性明显改善。相反,Plg-/-小鼠的动脉通畅性恶化。在静脉血栓形成中,α2-AP-/-小鼠血管闭塞时间显著延长(27.1±5.2分钟),而Plg-/-小鼠则略有缩短至6.5±2.5分钟。α2-AP-/-小鼠自发再灌注后的血管通畅性也有所改善,但Plg-/-小鼠没有。使用扫描电子显微镜(SEM)的组织学观察表明,纤维蛋白网在Plg-/-小鼠的损伤区域牢固固定,但在α2-AP-/-小鼠中则不然。任何类型小鼠的尾部出血时间均无差异。然而,与野生型小鼠相比,使用模板出血装置的再出血时间在α2-AP-/-小鼠中显著延长。总之,缺乏纤溶酶原会显著降低体内抗血栓活性,而α2-AP在小鼠静脉血栓的形成和清除中起更重要的作用。因此,抑制α2-AP可能是治疗静脉血栓形成和预防再血栓形成的有用工具。